Factory 99% Purity Inhibitors Sorafenib Powder CAS 284461-73-0
Basic info.
Product Name: Sorafenib
Molecular Formula: C21H16ClF3N4O3
CAS: 284461-73-0
Assay:99%
Synonyms:BAY43-9006; N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N- methylcarbamoyl)-4pyridyloxy]phenyl]urea;
Appearance:White to light yellow crystalline powder
Molecular Weight: 464.82495
Density: 1.454 g/cm3
Boiling Point: 523.3 °C at 760 mmHg
Melting Point: 202-204°C
Descrption
Sorafenib is a new multi-targeted oral drug for the treatment of tumors. Its primary development goal is to treat gastrointestinal stromal tumors and metastatic kidney cells that are not responsive or unbearable to standard therapies.
Sorafenib can selectively target certain proteins of the receptor, which is considered plays a role in molecular switching in the tumor growth process. Its indications have been in the approval by the FDA United States.
Application
1. Sorafenib tosylate (284461-73-0) is commonly used as a potent RAF kinase inhibitor.
2. Sorafenib tosylate (284461-73-0) is also used as antineoplastic drug.
3. Sorafenib is used to treat liver tumor cells that can not be surgically or distantly metastasized
4. Sorafenib is used to treat neovascular tumors that can not be operated
5. Sorafenib is used to treat radioactive iodine therapy is no longer effective local recurrence or metastasis, progressive differentiation of thyroid patients.
?
The COA of this product :
|
ITEMS |
SPECIFICATION |
TESTRESULTS |
|
Appearance |
Off-white or white powder |
Conforms |
|
Identification |
HPLC,NMR;LC-MS |
Conforms |
|
Related substances |
Individual impurity≤0.5% |
0.09% |
|
Total impurities≤1.0% |
0.20% |
|
|
Loss on drying |
≤0.5% |
0.3% |
|
Residue on ignition |
≤0.1% |
0.04% |
|
Heavy metals |
≤10ppm |
Conforms |
|
Assay |
≥98.0 % |
99.1% |